Emilio Bria
Emilio Bria
Oncologia Medica, Fondazione Policlinico Universitario 'A. Gemelli', I.R.C.C.S., UniversitÓ
Verified email at
Cited by
Cited by
Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
F Roila, J Herrstedt, M Aapro, RJ Gralla, LH Einhorn, E Ballatori, E Bria, ...
Annals of Oncology 21, v232-v243, 2010
Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy
R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ...
JAMA oncology 4 (11), 1543-1552, 2018
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ...
The Lancet Oncology 21 (7), 914-922, 2020
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials iná…
L Carbognin, S Pilotto, M Milella, V Vaccaro, M Brunelli, A Cali˛, ...
PloS one 10 (6), e0130142, 2015
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients
E Bria, C Nistico, F Cuppone, P Carlini, M Ciccarese, M Milella, G Natoli, ...
Cancer 106 (11), 2337-2344, 2006
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials
E Bria, F Cuppone, M Fornier, C Nistic˛, P Carlini, M Milella, I Sperduti, ...
Breast cancer research and treatment 109, 231-239, 2008
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role forá…
M Simbolo, A Mafficini, KO Sikora, M Fassan, S Barbi, V Corbo, ...
The Journal of pathology 241 (4), 488-500, 2017
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma
E Bajetta, M Di Bartolomeo, L Mariani, A Cassata, S Artale, S Frustaci, ...
Cancer 100 (2), 279-287, 2004
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospectiveá…
S Loibl, I Majewski, V Guarneri, V Nekljudova, E Holmes, E Bria, ...
Annals of Oncology 27 (8), 1519-1525, 2016
Patients’ perception of chemotherapy side effects: Expectations, doctor–patient communication and impact on quality of life–An Italian survey
D Lorusso, E Bria, A Costantini, M Di Maio, G Rosti, A Mancuso
European journal of cancer care 26 (2), e12618, 2017
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer: Meta‐analysis of randomized trials
F Cuppone, E Bria, S Verma, KI Pritchard, S Gandhi, P Carlini, M Milella, ...
Cancer: Interdisciplinary International Journal of the American Cancerá…, 2008
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel
A Scarpa, K Sikora, M Fassan, AM Rachiglio, R Cappellesso, D Antonello, ...
PloS one 8 (11), e80478, 2013
Gemcitabine‐based combinations for inoperable pancreatic cancer: have we made real progress? A meta‐analysis of 20 phase 3 trials
E Bria, M Milella, A Gelibter, F Cuppone, MS Pino, EM Ruggeri, P Carlini, ...
Cancer: Interdisciplinary International Journal of the American Cancerá…, 2007
Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center
A Fabi, A Felici, G Metro, A Mirri, E Bria, S Telera, L Moscetti, M Russillo, ...
Journal of Experimental & Clinical Cancer Research 30 (1), 1-7, 2011
Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma
M Milella, A Gelibter, SD Cosimo, E Bria, EM Ruggeri, P Carlini, ...
Cancer: Interdisciplinary International Journal of the American Cancerá…, 2004
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms TrialCrizotinib in ROS1-and METá…
L Landi, R Chiari, M Tiseo, F D'IncÓ, C Dazzi, A Chella, A Delmonte, ...
Clinical Cancer Research 25 (24), 7312-7319, 2019
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta‐analysis of randomized trials
E Bria, F Cuppone, D Giannarelli, M Milella, EM Ruggeri, I Sperduti, ...
Cancer: Interdisciplinary International Journal of the American Cancerá…, 2009
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
E Bria, M Milella, F Cuppone, S Novello, A Ceribelli, V Vaccaro, I Sperduti, ...
Annals of oncology 22 (10), 2277-2285, 2011
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis
A Nottegar, N Veronese, M Senthil, RM Roumen, B Stubbs, AH Choi, ...
European Journal of Surgical Oncology (EJSO) 42 (7), 919-925, 2016
mTOR cross-talk in cancer and potential for combination therapy
F Conciatori, L Ciuffreda, C Bazzichetto, I Falcone, S Pilotto, E Bria, ...
Cancers 10 (1), 23, 2018
The system can't perform the operation now. Try again later.
Articles 1–20